Mineralys Therapeutics Inc’s recent filing unveils that its CFO and Secretary Levy Adam Scott unloaded Company’s shares for reported $0.45 million on Oct 13 ’25. In the deal valued at $42.01 per share,10,758 shares were sold. As a result of this transaction, Levy Adam Scott now holds 116,865 shares worth roughly $4.74 million.
Then, Congleton Jon sold 15,100 shares, generating $644,327 in total proceeds. Upon selling the shares at $42.67, the Chief Executive Officer now owns 831,305 shares.
Before that, Rodman David Malcom sold 10,369 shares. Mineralys Therapeutics Inc shares valued at $445,982 were divested by the Chief Medical Officer at a price of $43.01 per share. As a result of the transaction, Rodman David Malcom now holds 71,155 shares, worth roughly $2.89 million.
Jefferies initiated its Mineralys Therapeutics Inc [MLYS] rating to a Hold in a research note published on June 11, 2025; the price target was $15. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early July with a ‘”a Buy”‘ rating. Goldman began covering MLYS with “Buy” recommendation on April 02, 2024. Wells Fargo started covering the stock on March 07, 2023. It rated MLYS as “an Overweight”.
Price Performance Review of MLYS
On Monday, Mineralys Therapeutics Inc [NASDAQ:MLYS] saw its stock jump 1.65% to $40.56. Over the last five days, the stock has lost -8.15%. Mineralys Therapeutics Inc shares have risen nearly 196.71% since the year began. Nevertheless, the stocks have risen 229.49% over the past one year. While a 52-week high of $44.80 was reached on 10/16/25, a 52-week low of $8.24 was recorded on 02/25/25.
Levels Of Support And Resistance For MLYS Stock
The 24-hour chart illustrates a support level at 39.84, which if violated will result in even more drops to 39.12. On the upside, there is a resistance level at 41.44. A further resistance level may holdings at 42.32.
How much short interest is there in Mineralys Therapeutics Inc?
A steep rise in short interest was recorded in Mineralys Therapeutics Inc stocks on 2025-10-15, dropping by -0.45 million shares to a total of 7.13 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 7.58 million shares. There was a decline of -6.27%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 07, 2023 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $45 price target.
